Breast Cancer | Norton Healthcare

Indication: Breast Cancer

A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens

Sub-indication: Breast Cancer

Drug

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: National Surgical Adjuvant Breast and Bowel Projec

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.